This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This is not a full-text translation of the original article. It is an independent detailed introduction based on the public paper, organizing its inclusion criteria, confirmable number of cases, principal clinical findings, and limits of causal inference. The original asks whether kambô can be regarded as safe because it is “natural,” using prior acute poisoning cases to examine the question.
The subject is adverse events after unfractionated Phyllomedusa bicolor skin secretion was applied to people. This is not a review evaluating receptor activity of isolated peptides or cell experiments as treatment effects. Although peptides may have been present in every case, the amount and composition of the actual secretion were rarely measured, making it impossible to definitively assign an individual symptom to one molecule.
Study design
The authors searched PubMed for “kambo” or “Phyllomedusa bicolor” and examined clinical cases published from 2010 through 2021 that included adverse events after kambô use. They excluded studies limited to the pharmacology of individual peptides and narrative reviews that did not describe actual poisoning cases. The search initially yielded 50 publications; after assessment of titles, abstracts, and full texts, the final case series contained 11 cases.
For each case, the authors extracted and compared age, sex, medical history, application site, time to onset, symptoms, laboratory findings, imaging and physiologic tests, associated condition, treatment, and time to discharge. They also proposed an algorithm for diagnosis and management of a suspected case, but this was not a standard-of-care guideline whose efficacy had been validated in a comparative trial.
Content
The 11 cases involved 9 women and 2 men, aged 24–62 years, with a mean age of 38.6 years. Medical histories included mood disorders, alcohol, cannabis, and nicotine use, overweight, coronary atherosclerosis, and left ventricular hypertrophy. 3 cases documented drinking several liters of water after application, and symptoms began within minutes to as late as 12 hours.
Symptoms involved multiple systems and included nausea and vomiting, diarrhea, abdominal discomfort, circulatory changes such as tachycardia, respiratory difficulty, seizures or psychiatric symptoms, weakness and muscle spasms, and electrolyte abnormalities. Individual cases showed elevations in muscle and liver enzymes, leukocytosis, lactic acidosis, low Na, K, Mg, or P, and thrombocytopenia.
Toxicologic confirmation of kambô constituents was extremely limited. Deltorphin A was detected postmortem in 1 fatal case. Benzodiazepines or cannabinoids were detected in some other cases. In many reports, the constituents, purity, actual amount administered, and co-used substances could not be established.
Results
The associated conditions in the assembled cases were SIADH in 5, acute kidney injury in 1, dermatomyositis in 1, esophageal rupture related to intense vomiting in 1, a severe psychotic state in 1, toxic hepatitis in 1, and death in 1. Affected systems were categorized as gastrointestinal in 8 cases, neurologic in 7, musculoskeletal in 7, and cardiovascular in 4.
Treatment varied according to the condition in each case and included electrolyte and fluid management, respiratory management, antiemetics, antipsychotics, benzodiazepines, supportive treatment for liver injury, and surgery for esophageal rupture. Time to discharge or recovery ranged from 1 hour to 3 months, and mean hospital stay was reported as approximately 1 week. Because the series includes a death, the description that “many events were reversible” cannot serve as a safety guarantee.
Limitations
PubMed was the only database searched, and the period and search terms were limited. Severe or unusual events are more likely to be published as case reports, while mild cases may not be captured. Without a denominator representing total uses, proportions such as 45.45% for SIADH describe the composition of these 11 published cases, not incidence among actual users.
Cases differed in secretion source, storage, amount, burn points, water intake, accompanying ritual, scope of testing, and diagnostic criteria. Kambô constituents were analytically confirmed in few cases, and temporal association alone cannot establish kambô as the sole cause of every event. The proposed algorithm was also not tested within this review for improved outcomes.
Safety
This collection shows that acute events including hyponatremia, seizures, organ injury, esophageal rupture, and death have been reported. Heavy water intake, intense vomiting, pre-existing heart disease, other substances, and repeated use may contribute to pathways of harm. A combination of characteristic burn points and gastrointestinal, neurologic, or circulatory symptoms may provide clinicians with a clue to possible exposure.
This resource does not provide diagnosis, treatment procedures, or self-management. Required care differed among cases, and a public review cannot establish home responses or safe conditions of administration.
Source and rights
Original source: Sacco MA, et al. Kambo: Natural drug or potential toxic agent? A literature review of acute poisoning cases. Toxicology Reports. 2022;9:905–913. DOI: 10.1016/j.toxrep.2022.04.005. PMID 35515815; PMCID PMC9061256.
The original article is published under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND 4.0). To respect the no-derivatives condition, this page is an independently worded introduction to bibliographic facts and research points, not a translation or adaptation of the original. It does not reproduce the source’s table, algorithm, figure, or prose.